



Cervical Chronicles: Navigating the Evolving Landscape of Treatment

Clinical Brief #2: Current Standard of Care Therapy for Metastatic Cervical Cancer

References

Tweet 2

KEYTRUDA® (pembrolizumab). Prescribing information. Merck Sharp & Dohme Corp. Approved 2014. Revised August 2023.

National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®): Cervical Cancer (v1.2023). Updated April 28, 2023. Accessed May 5, 2023.

TIVDAK™ (tisotumab vedotin-tftv). Prescribing information. Seagen Inc. Approved 2021. Revised July 2023.

Additional References

AstraZeneca. Update on CALLA phase III trial of concurrent use of Imfinzi and chemoradiotherapy in locally advanced cervical cancer. Updated March 24, 2022. Accessed September 22, 2023.
<https://www.astrazeneca.com/media-centre/press-releases/2022/update-on-calla-phase-iii-trial-for-imfinzi.html>

Coleman RL, Lorusso D, Gennigens C, et al. Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol*. 2021;22(5):609-619. doi:10.1016/S1470-2045(21)00056-5

Lorusso D, Xiang Y, Colombo N, et al. 261 ENGOT-cx11/GOG 3047/KEYNOTE-A18: phase 3 randomized study of pembrolizumab + chemoradiotherapy for high-risk locally advanced cervical cancer. *Int J Gynecol Cancer*. 2021;31:A19-A20. doi:10.1136/ijgc-2021-esgo.21

Lorusso D, Xiang Y, Hasegawa K, et al. LBA38 Pembrolizumab plus chemoradiotherapy for high-risk locally advanced cervical cancer: a randomized, double-blind, phase III ENGOT-cx11/GOG-3047/KEYNOTE-A18 study. *Ann Oncol*. 2023;34:S1279-S1280. doi:10.1016/j.annonc.2023.10.032

Monk BJ, Colombo N, Tewari KS, et al. KEYNOTE-826: Final overall survival results from a randomized, double-blind, phase 3 study of pembrolizumab + chemotherapy vs placebo + chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. *J Clin Oncol*. 2023;41(16_suppl):5500. doi:10.1200/JCO.2023.41.16_suppl.5500

Monk B, Toita T, Wu X, et al. O001/#504 Durvalumab, in combination with and following chemoradiotherapy, in locally advanced cervical cancer: results from the phase 3 international, randomized, double-blind, placebo-controlled calla trial. *Int J Gynecol Cancer*. 2022;32:A2-A3. doi:10.1136/ijgc-2022-igcs.3

Glossary

≥2L, second line or subsequent

1L, first line

AE, adverse event

BEV, bevacizumab

CI, confidence interval

CCRT, concurrent chemotherapy (cisplatin + EBRT, followed by brachytherapy)

Chemo, chemotherapy

CPS, Combined Positive Score

CR, complete response

dMMR, mismatch repair deficient

DOR, duration of response

HR, hazard ratio

IrAE, immune-related adverse event

MSI-H, microsatellite instability high

N+, node positive

ORR, objective response rate

OS, overall survival

PD-L1, programmed death-ligand 1

Pembro, pembrolizumab

PFS, progression-free survival

QOL, quality of life

SOC, standard of care

TF, tissue factor

TMB-H, tumor mutational burden high

TRAE, treatment-related adverse event

w/, with

yo, year old